Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

5.5%

18 terminated/withdrawn out of 326 trials

Success Rate

89.0%

+2.4% vs industry average

Late-Stage Pipeline

10%

34 trials in Phase 3/4

Results Transparency

11%

16 of 146 completed trials have results

Key Signals

52 recruiting16 with results14 terminated4 withdrawn

Enrollment Performance

Analytics

N/A

133(57.3%)

Phase 2

46(19.8%)

Phase 3

23(9.9%)

Phase 1

18(7.8%)

Phase 4

11(4.7%)

Early Phase 1

1(0.4%)

232Total

N/A(133)

Phase 2(46)

Phase 3(23)

Phase 1(18)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (326)

Showing 20 of 326 trials

NCT07160686Phase 3Recruiting

Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment

Role: lead

NCT06286709Phase 2Recruiting

FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis

Role: lead

NCT07837414Not ApplicableNot Yet Recruiting

Comparative Effectiveness Randomised Controlled Trial of Hybrid Muscle Conditioning

Role: collaborator

NCT07828626Recruiting

Benefits of Retained Insulin for Good Health

Role: collaborator

NCT03633162Recruiting

Maternal Grandmothers in the Born in Guangzhou Cohort Study

Role: collaborator

NCT07785076Not Yet Recruiting

SurgWeek-2: Identifying the Global Burden of Post Operative Complications: an International Prospective Cohort Study Protocol

Role: lead

NCT07773142Not ApplicableRecruiting

Skeletal Muscle Adaptations to Peptide-Supplemented Resistance Exercise Training

Role: lead

NCT07774676Recruiting

Effects of Obesity on Autophagy and mTORC1 Signalling in Skeletal Muscle

Role: lead

NCT07285811Not ApplicableRecruiting

GLycaemic Outcomes With Whey Protein in ageING

Role: lead

NCT07440290Phase 2Recruiting

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

Role: collaborator

NCT04173533Phase 3Completed

Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT

Role: lead

NCT03899337Phase 2Active Not Recruiting

A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome

Role: lead

NCT04543097Not ApplicableTerminated

Work And Vocational advicE Study - Effectiveness of Adding a Brief Vocational Support Intervention to Usual Primary Care

Role: collaborator

NCT05148702Phase 3Active Not Recruiting

EXTENDed Antibiotic Durations Compared to Standard Durations for Patients With Complicated Intra-abdominal Infection.

Role: collaborator

NCT07599683Not ApplicableRecruiting

Effect of Low Dose Galactose on Glycaemia and Glucose Kinetics

Role: collaborator

NCT05722886Phase 2Recruiting

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Role: collaborator

NCT02724163Phase 3Active Not Recruiting

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia

Role: lead

NCT02945566Phase 2Active Not Recruiting

Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?

Role: lead

NCT02991105Active Not Recruiting

Epidemiology of Complications After Solid Organ Transplantation - EpCOT Study

Role: lead

NCT06167928Recruiting

Developing Allogeneic Musculoskeletal Therapies

Role: collaborator